<DOC>
	<DOCNO>NCT00931801</DOCNO>
	<brief_summary>The purpose Phase IV pilot study evaluate safety , tolerability , satisfaction nucleoside analog reverse-transcriptase inhibitor ( NRTI ) spar regimen participant fully suppress atazanavir/ritonavir base highly active antiretroviral therapy ( HAART ) regimen plus emtricitabine/tenofovir ( Truvada ) . Several pharmacologic factor support concept include favorable drug interaction atazanavir raltegravir . Participants randomize either continue current regimen one two study arm ( atazanavir 300mg plus ritonavir 100mg daily plus raltegravir 400mg twice daily atazanavir 300mg twice daily plus raltegravir 400mg twice daily ) . Participants follow 48 week safety , tolerability , satisfaction . After baseline , participant six clinic visit evaluation lab .</brief_summary>
	<brief_title>BATAR : Individuals Currently Taking Boosted Atazanavir Part HIV Treatment Regimen Will Evaluated See Substituting Raltegravir Nucleoside Transcriptase Inhibitors Will Safe Well Tolerated .</brief_title>
	<detailed_description />
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>HIV1 infection Treatment stable antiretroviral regiment contain boost atazanavir , tenofovir emtricitabine screen least 90 day prior screen No plan make change HIV treatment regimen ( require study ) next 48 week Undetectable HIV RNA screening AND HIV RNA &gt; 200 copy 180 day period prior screen CD4 count &gt; 200 No evidence resistance drug 3 arm , prior resistance test available Subjects , opinion treat physician , would candidate switch antiretroviral medication Women childbearing potential must use adequate method contraception avoid pregnancy throughout study 8 week last dose study drug Ability willingness provide write informed consent comply protocol requirement Prior exposure raltegravir elvitegravir Women pregnant , breastfeeding , positive pregnancy test Sexually active fertile men use effective birth control female partner childbearing potential Women childbearing potential unwilling unable use acceptable method avoid pregnancy entire study period 8 week last dose study drug Life expectancy le 6 month Presence currently active AIDS defining condition exception stable cutaneous Kaposi 's sarcoma Treatment protonpump inhibitor H2receptor antagonist ECG demonstrate atrioventricular block , prolong QRS interval great 12 m , know complete bundle branch block Acute chronic hepatitis B infection evidence presence hepatitis B surface antigen absence hepatitis B surface antibody Clinical laboratory evidence significantly decrease hepatic function decompensation irrespective liver enzyme level Prisoners subject involuntarily incarcerate Subjects compulsorily detain treatment either psychiatric physical ( e.g. , infectious disease ) illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>AIDS</keyword>
	<keyword>HIV</keyword>
	<keyword>Atazanavir</keyword>
	<keyword>Raltegravir</keyword>
	<keyword>Tenofovir</keyword>
	<keyword>protease inhibitor</keyword>
</DOC>